19.59
-0.23 (-1.16%)
-0.23 (-1.16%)
Upgrade to Real-Time
Afterhours (Closed)
Volume | 173,596 |
|
|||||
News | - | ||||||
Day High | 19.80 | Low High |
|||||
Day Low | 19.45 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Stevanato Group SpA | STVN | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
19.63 | 19.45 | 19.80 | 19.59 | 19.82 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,175 | 173,596 | $ 19.65 | $ 3,411,127 | - | 13.355 - 21.49 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:00:00 | 6,248 | $ 19.59 | USD |
Stevanato Group SpA Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 5.19B | 264.70M | 33.07M | $ 959.87M | $ 131.41M | 0.60 | 35.20 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | 0.27% | 06/13/22 | - | - |
Stevanato News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical STVN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 20.51 | 20.82 | 19.43 | 19.84 | 192,691 | -0.92 | -4.49% |
1 Month | 19.17 | 21.00 | 17.30 | 19.76 | 260,607 | 0.42 | 2.19% |
3 Months | 15.03 | 21.00 | 13.71 | 17.29 | 310,652 | 4.56 | 30.34% |
6 Months | 18.59 | 21.00 | 13.71 | 17.07 | 309,619 | 1.00 | 5.38% |
1 Year | 17.81 | 21.49 | 13.355 | 16.90 | 313,708 | 1.78 | 9.99% |
3 Years | 16.65 | 29.18 | 13.355 | 19.49 | 394,349 | 2.94 | 17.66% |
5 Years | 16.65 | 29.18 | 13.355 | 19.49 | 394,349 | 2.94 | 17.66% |
Stevanato Description
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato's revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America. |